Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans

Hypertension

Volumn 43, Issue 4, 2004, Pages 785-790

  Azizi, Michel ^a   Bissery, Alvine ^a   Lamarre Cliche, Maxime ^b   Ménard, Joël ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Angiotensin antagonist; Blood pressure; Renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; RENIN; SODIUM ION; VALSARTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; FEEDBACK SYSTEM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AREA UNDER CURVE; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CROSS-OVER STUDIES; DIET, SODIUM-RESTRICTED; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FUROSEMIDE; HUMANS; JUXTAGLOMERULAR APPARATUS; MALE; RENIN; RENIN-ANGIOTENSIN SYSTEM; REPRODUCIBILITY OF RESULTS; TETRAZOLES; VALINE; VARIATION (GENETICS);

EID: 1642542430     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000125698.00128.64     Document Type: Article

References (25)

1. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL. Dose-ranging study of the angiotensin type I receptor antagonist Losartan (DuP753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol. 1993;21:732-738.
2. MacFadyen RJ, Elliott HL, Meredith PA, Reid JL. Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive man. Br J Clin Pharmacol. 1993;35:299-301.
3. Ménard J, Boger RS, Moyse DM, Guyene TT, Glasmann HN, Kleinert HD. Dose-dependent effects of the renin inhibitor, zankiren HCL, after a single oral dose in mildly sodium depleted normotensive volunteers. Circulation. 1995;91:330-338.
4. Bing J. Rapid marked increase in plasma renin in rats treated with inhibitors of the renin system. Effects of 1-sar-8-ala-angiotensin II and of a synthetic converting enzyme inhibitor (nonapeptide, SQ 20.881) on normal and adrenalectomized rats. Acta Pathol Microbiol Scand [A]. 1973;81:376-378.
5. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Ménard J. Additive effects of combined angiotensin converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92:825-834.
6. Azizi M, Chatellier G, Guyene TT, Ménard J. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. J Hypertens. 1999;17:561-568.
7. Delacretaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension. 1995;25:14-21.
8. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997;52:115-120.
9. Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokin. 1997;32:1-29.
10. Gasc JM, Monnot C, Clauser E, Corvol P. Co-expression of type 1 angiotensin II receptor (ATIR) and renin mRNAs in juxtaglomerular cells of the rat kidney. Endocrinology. 1993;132:2723-2725.
11. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor? Hypertension. 2003;41:31-36.
12. Maillard MP, Mazzolai L, Daven V, Centeno C, Nussberger J, Brunner HR, Burnier M. Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay. Am J Hypertens. 1999;12:1201-1208.
13. Maillard MP, Wurzner G, Nussberger J, Centeno C, Burnier M, Brunner HR. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther. 2002;71:68-76.
14. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three ATI receptor antagonists. Hypertension. 1999;33:850-855.
15. Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, Nishikawa K. Candesartan (CV-11974) dissociates slowly from the angiotensin ATI receptor. Eur J Pharmacol. 1997;319:137-146.
16. Malerczyk C, Fuchs B, Belz GG, Roll S, Butzer R, Breithaupt-Grogler K, Herrmann V, Magin SG, Hogemann A, Voith B, Mutschler E. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. Br J Clin Pharmacol. 1998;45:567-573.
17. Rowland M, Tozer TN. Variability. In: Rowland M, Tozer TN, eds. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, London: Lea & Febiger; 1989:197-212.
18. Luft FC, Grim CE, Higgins JT, Jr., Weinberger MH. Differences in response to sodium administration in normotensive white and black subjects. J Lab Clin Med. 1977;90:555-562.
19. Grim C, Luft FC, Miller JZ, Rose RJ, Christian JC, Weinberger MH. An approach to the evaluation of genetic influences on factors that regulate arterial blood pressure in man. Hypertension. 1980;2:I34-I42.
20. Jeunemaitre X, Vuagnat A, Hopkins P, Ménard J, Williams G, Corvol P. Familial correlations of plasma renin in hypertensive sibling pairs. J Hypertens. 1997;15:S86.
21. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100:2312-2318.
22. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
23. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
24. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
25. Marre M, Lièvre M, Chatellier G, Mann JFE, Passa P, Ménard J. Effects of low-dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004;328:495-500.